Clinical Cancer Research, Vol 3, Issue 11 2137-2142, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Analysis of retinoic acid receptor beta expression in normal and malignant laryngeal mucosa by a sensitive and routine applicable reverse transcription-polymerase chain reaction enzyme-linked immunosorbent assay method

L Castillo, G Milano, J Santini, F Demard and V Pierrefite
Department of Head and Neck Surgery, Pasteur Hospital, 06002 Nice cedex 1, France.

Retinoic acid receptor beta (RAR-beta) seems to be a useful intermediate marker in trials of retinoids, and the aim of this work was to describe a fast, sensitive, and routine applicable method to measure RAR-beta expression in tumor biopsies. We developed a new technique combining reverse transcription-PCR with a colorimetric ELISA detection of amplification products. The principle of this nonradioactive method is based on digoxigenin labeling of PCR products during amplification. Amplified DNA is hybridized with a biotinylated capture probe. The generated hybrid is immobilized on a streptavidin-coated microtiter plate, and detection is performed with the use of an antidigoxigenin peroxidase conjugate. We applied this method to quantify the expression of RAR-beta and an internal control (beta2 microglobulin) in laryngeal tumors. We found a detection threshold at 50 pg of PCR products, which represents a 100-fold improvement when compared to the detection limit of ethidium bromide detection. The method was reproducible (intra- and interassay reproducibilities at 7 and 5%, respectively). We used this technique for determining RAR-beta expression in 20 patients with laryngeal carcinoma and in 20 patients without cancer. The data show that the value of the RAR-beta:beta2 microglobulin ratio is decreased in tumoral versus nontumoral specimens (P = 0.0012), which is consistent with previously published results.

This article has been cited by other articles:

				P. Germain, P. Chambon, G. Eichele, R. M. Evans, M. A. Lazar, M. Leid, A. R. De Lera, R. Lotan, D. J. Mangelsdorf, and H. Gronemeyer International Union of Pharmacology. LX. Retinoic Acid Receptors Pharmacol. Rev., December 1, 2006; 58(4): 712 - 725. [Abstract] [Full Text] [PDF]

				E. Filipski, V. M. King, M.-C. Etienne, X. Li, B. Claustrat, T. G. Granda, G. Milano, M. H. Hastings, and F. Levi Persistent twenty-four hour changes in liver and bone marrow despite suprachiasmatic nuclei ablation in mice Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2004; 287(4): R844 - R851. [Abstract] [Full Text] [PDF]

				R. Lotan Are We Ready to Use Surrogate End Points and Surrogate Tissues to Evaluate Response to Chemopreventive and Therapeutic Intervention? Clin. Cancer Res., June 1, 2000; 6(6): 2126 - 2128. [Full Text]

				R. Lotan Aberrant Expression of Retinoid Receptors and Lung Carcinogenesis J Natl Cancer Inst, June 16, 1999; 91(12): 989 - 991. [Full Text] [PDF]